8-K/A: Prestige Consumer Healthcare Completes OTC Wellness Acquisition

Prestige Consumer Healthcare Inc. files an 8-K/A to provide financial statements and pro forma information related to its acquisition of the OTC Wellness Business from Foundation Consumer Brands, LLC.

Summary

• This filing is an amendment (8-K/A) to a previous Current Report on Form 8-K, providing necessary financial statements and pro forma information for the acquisition of the OTC Wellness Business from Foundation Consumer Brands, LLC.
• The acquisition, which closed on June 12, 2026, involved brands such as Breathe Right, Dimetapp, Anbesol, and others.
• The filing includes audited combined financial statements for the OTC Wellness Business for the year ended December 31, 2025, and unaudited condensed combined financial statements for the three months ended March 31, 2026 and 2025.
• Pro forma condensed combined financial information as of March 31, 2026, and for the year ended March 31, 2026, is also provided.
• The acquisition was financed through a $1,045.0 million term loan and cash on hand.
• Prestige also amended its asset-based revolving line of credit, increasing commitments to $225 million and extending the maturity date to June 12, 2031.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it provides necessary financial disclosures for a significant acquisition, but also highlights increased debt and pro forma earnings dilution.

Positives

• Completion of the acquisition of the OTC Wellness Business, adding established brands to Prestige's portfolio.
• Secured $1,045.0 million in term loan financing to fund the acquisition.
• Increased asset-based revolving credit facility commitments to $225 million and extended its maturity to June 12, 2031, providing enhanced financial flexibility.
• The pro forma combined statement of income for the year ended March 31, 2026, shows a projected net income of $180.6 million on total revenues of $1,284.8 million.

Negatives

• The pro forma combined statement of income for the year ended March 31, 2026, shows a significant increase in interest expense to $104.5 million due to the new term loan.
• The acquisition resulted in substantial intangible assets ($3.25 billion) and goodwill ($663.7 million) on the pro forma balance sheet, which are subject to impairment risk.
• The pro forma net income of $180.6 million for the year ended March 31, 2026, is lower than the historical net income of Prestige Consumer Healthcare Inc. ($190.3 million) before the acquisition, indicating a dilutive effect on earnings per share in the pro forma presentation.

Risks

• The pro forma financial statements are based on preliminary valuations and estimates, and actual results may differ materially.
• The acquired OTC Wellness Business is subject to risks associated with the consumer health industry, including competition, changing consumer preferences, and regulatory changes.
• The significant debt incurred for the acquisition increases financial leverage and interest expense, potentially impacting future profitability and financial flexibility.
• Intangible assets and goodwill are subject to impairment testing, and adverse economic conditions or business performance could lead to significant impairment charges.

Future Outlook

The pro forma financial information illustrates the potential financial position and results of operations of the combined entity following the acquisition. The company also anticipates the acquisition of LaCorium Health in the second quarter of fiscal year 2027, which may be partially financed by an additional draw on the term loan facility.

Management Comments

• Management believes that showing combined financial statements of the brands to be acquired is the most accurate and reasonable method for preparing these financial statements.
• Management considers the allocation methodologies used for corporate expenses to be reasonable and appropriate reflections of the related expenses attributable to the OTC Wellness Business.
• Management believes that any liability resulting from lawsuits arising in the ordinary course of business would not be material in relation to the OTC Wellness Business's condensed combined financial position, results of operations, and cash flows.

Industry Context

StockSavvy.ai notes that this filing reflects a significant consolidation trend in the consumer healthcare sector, where established companies are acquiring complementary brands to expand their market reach and product portfolios. The financing structure, including a large term loan and an expanded revolving credit facility, is typical for such strategic acquisitions in the industry.

Comparison to Industry Standards

• The acquisition price of $1,045.0 million for the OTC Wellness Business, which includes brands like Breathe Right and Dimetapp, appears to be a significant investment. Without specific multiples or comparable transaction data within this filing, a direct comparison to industry standards for similar brand portfolios is difficult.
• The use of a term loan for acquisition financing is standard practice. The interest rate structure (Term SOFR plus 2.00% or alternate base rate) and amortization schedule (0.25% quarterly) are within typical market terms for corporate debt.
• The increase in the asset-based revolving credit facility to $225 million and extension to 2031 aligns with industry practices for providing ongoing working capital and operational flexibility for larger, consolidated entities.

Legal Proceedings

• Management believes that any liability resulting from lawsuits arising in the ordinary course of business would not be material.
• As of March 31, 2026, there is no pending or threatened litigation against FCB that is related to the operations of the OTC Wellness Business or employees.

Related Party Transactions

• FCB entered into advisory agreements with two affiliates that provided consulting and advisory services, with payments allocated to the OTC Wellness Business recorded in other expenses, net ($101,000 in Q1 2026, $211,000 in Q1 2025 for Affiliate 1; $15,000 in Q1 2026, $8,000 in Q1 2025 for Affiliate 2).

Stakeholder Impact

• Shareholders: The acquisition increases the company's asset base and brand portfolio, but also increases debt and may lead to pro forma earnings dilution in the short term.
• Creditors: The significant increase in debt ($1,045 million term loan) impacts the company's leverage ratios and debt servicing obligations.
• Suppliers: The integration of the OTC Wellness Business may lead to changes in procurement and supply chain management.
• Employees: While not explicitly detailed, acquisitions often lead to integration efforts that can impact employees.

Next Steps

• The company is expected to finalize the valuation of acquired assets and liabilities related to the OTC Wellness Business.
• The company anticipates closing the LaCorium Health Acquisition in the second quarter of fiscal year 2027.
• The company will continue to manage its increased debt obligations and monitor its financial leverage.

Key Dates

Recommendation

The filing provides essential financial details for a significant acquisition, which is a positive step. However, the substantial increase in debt, the pro forma dilution in EPS, and the preliminary nature of the financial information warrant a cautious 'hold' stance until the full integration and financial performance of the acquired business become clearer.

Keywords

Prestige Consumer Healthcare, 8-K/A, OTC Wellness Business, Foundation Consumer Brands, Acquisition, Financial Statements, Pro Forma, Breathe Right, Term Loan, Credit Facility